FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine and concerns a means for correcting the pathological conditions of cells of organs and tissues and/or human organs and tissues based on the CLCA2 gene associated with a quantitative decrease in the calcium chloride-activated channel-2 protein, where the cells of organs and tissues are selected from cells of fibroblasts, keratocytes and epithelial cells of the eye, cells of the epithelium of the oral mucosa; organs and tissues are selected from the skin, mucous membrane of the oral cavity or human muscle tissue, which is a set of biologically active gene therapy substances, each of which is a gene therapy substance, selected from the group of gene therapy substances, each being a genetic construct based on a vector plasmid, comprising the cDNA of the CLCA2 gene with the coding sequence of the calcium chloride-activated channel-2 protein, with deletions of 5' and 3' non-translated regions, in combination with a transport molecule or without it. Group of inventions also relates to a method for producing said agent; a method of using said means for correcting the pathological conditions of cells of organs and tissues and/or human organs and tissues based on the CLCA2 gene associated with a quantitative decrease in the CLCA2 protein.
EFFECT: group of inventions provides a high and stable level of the target protein in the cells.
5 cl, 20 dwg, 18 ex
